Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO)

Thomas B Brunner, Gerhard G Grabenbauer, Thomas Meyer, Henriette Golcher, Rolf Sauer, Werner Hohenberger, Thomas B Brunner, Gerhard G Grabenbauer, Thomas Meyer, Henriette Golcher, Rolf Sauer, Werner Hohenberger

Abstract

Background: The disappointing results of surgical therapy alone of ductal pancreatic cancer can only be improved using multimodal approaches. In contrast to adjuvant therapy, neoadjuvant chemoradiation is able to facilitate resectability with free margins and to lower lymphatic spread. Another advantage is better tolerability which consecutively allows applying multimodal treatment in a higher number of patients. Furthermore, the synopsis of the overall survival results of neoadjuvant trials suggests a higher rate compared to adjuvant trials.

Methods/design: As there are no prospectively randomised studies for neoadjuvant therapy, the Interdisciplinary Study Group of Gastrointestinal Tumours of the German Cancer Aid has started such a trial. The study investigates the effect of neoadjuvant chemoradiation in locally resectable or probably resectable cancer of the pancreatic head without distant metastasis on median overall survival time compared to primary surgery. Adjuvant chemotherapy is integrated into both arms.

Discussion: The protocol of the study is presented in condensed form after an introducing survey on adjuvant and neoadjuvant therapy in pancreatic cancer.

Figures

Figure 1
Figure 1
Treatment schedule.

References

    1. Deutschland ABK. Krebs in Deutschland. Häufigkeiten und Trends. 3rd edition 2000.
    1. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27:324–329. doi: 10.1007/s00268-002-6659-z.
    1. Hohenberger W, Kastl S. [Neoadjuvant and adjuvant therapy of ductal pancreatic carcinoma] ZentralblChir. 2000;125:348–355.
    1. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer. 1976;37:1519–1524. doi: 10.1002/1097-0142(197603)37:3<1519::AID-CNCR2820370340>;2-O.
    1. Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Adjuvant therapy of resected adenocarcinoma of the pancreas. IntJRadiatOncolBiolPhys. 1991;21:1137–1143.
    1. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72:2118–2123. doi: 10.1002/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>;2-4.
    1. Foo ML, Gunderson LL, Nagorney DM, McLlrath DC, van Heerden JA, Robinow JS, Kvols LK, Garton GR, Martenson JA, Cha SS. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. IntJRadiatOncolBiolPhys. 1993;26:483–489.
    1. Morganti AG, Valentini V, Macchia G, Alfieri S, Trodella L, Brizi MG, Bossola M, Ziccarelli L, Doglietto GB, Cellini N. Adjuvant radiotherapy in resectable pancreatic carcinoma. Eur J Surg Oncol. 2002;28:523–530. doi: 10.1053/ejso.2002.1289.
    1. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA, Evans DB. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas [see comments] JClinOncol. 1997;15:928–937.
    1. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection [published erratum appears in Arch Surg 1986 Sep;121(9):1045] ArchSurg. 1985;120:899–903.
    1. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. AnnSurg. 1999;230:776–782.
    1. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210. doi: 10.1056/NEJMoa032295.
    1. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–1585. doi: 10.1016/S0140-6736(01)06651-X.
    1. Choti MA. Adjuvant therapy for pancreatic cancer--the debate continues. N Engl J Med. 2004;350:1249–1251. doi: 10.1056/NEJMe048002.
    1. Neuhaus P, Oettle H, Post S, Gellert K, Ridwelski K, Schramm H, Zülke C, Fahlke G, Langrehr J, Riess H. JClinOncol. Vol. 23. Orlando, FL ; 2005. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. LBA4013; p. 1029s.
    1. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama. 2007;297:267–277. doi: 10.1001/jama.297.3.267.
    1. Knaebel HP, Marten A, Schmidt J, Hoffmann K, Seiler C, Lindel K, Schmitz-Winnenthal H, Fritz S, Herrmann T, Goldschmidt H, Mansmann U, Debus J, Diehl V, Buchler MW. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759] BMC Cancer. 2005;5:37. doi: 10.1186/1471-2407-5-37.
    1. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. JGastrointestSurg. 2001;5:121–130. doi: 10.1016/S1091-255X(01)80023-8.
    1. Snady H, Bruckner H, Siegel J, Cooperman A, Neff R, Kiefer L. Endoscopic ultrasonographic criteria of vascular invasion by potentially resectable pancreatic tumors. GastrointestEndosc. 1994;40:326–333.
    1. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. AnnSurgOncol. 2001;8:123–132.
    1. White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS, Jowell PS, Clary BM, Pappas TN, Tyler DS. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12:214–221. doi: 10.1245/ASO.2005.03.105.
    1. Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S. Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. American journal of surgery. 2004;187:736–740. doi: 10.1016/j.amjsurg.2003.07.031.
    1. Ando N, Nakao A, Nomoto S, Takeda S, Kaneko T, Kurokawa T, Nonami T, Takagi H. Detection of mutant K-ras in dissected paraaortic lymph nodes of patients with pancreatic adenocarcinoma. Pancreas. 1997;15:374–378. doi: 10.1097/00006676-199711000-00007.
    1. Niedergethmann M, Rexin M, Hildenbrand R, Knob S, Sturm JW, Richter A, Post S. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. The American journal of surgical pathology. 2002;26:1578–1587. doi: 10.1097/00000478-200212000-00005.
    1. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579. doi: 10.1016/S1091-255X(00)80105-5.
    1. Merkel S, Mansmann U, Meyer T, Papadopoulos T, Hohenberger W, Hermanek P. Confusion by frequent changes in staging of exocrine pancreatic carcinoma. Pancreas. 2004;29:171–178. doi: 10.1097/00006676-200410000-00001.
    1. Wayne JD, Wolff RA, Pisters PW, Evans DB. Multimodality management of localized pancreatic cancer. Cancer J. 2001;7 Suppl 1:S35–46.
    1. Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer. 2003;34:121–128. doi: 10.1385/IJGC:34:2-3:121.
    1. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000;89:314–327. doi: 10.1002/1097-0142(20000715)89:2<314::AID-CNCR16>;2-V.
    1. Wilkowski R, Thoma M, Heinemann V, Rau HG, Wagner A, Stoffregen C, Duhmke E. Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer - feasible and effective. StrahlentherOnkol. 2003;179:78–86. doi: 10.1007/s00066-003-1036-x.
    1. Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA. Neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am. 2004;13:639–61, ix. doi: 10.1016/j.soc.2004.06.007.
    1. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, Lawrence TS, McGinn CJ. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7:766–772. doi: 10.1016/S1091-255X(03)00113-6.
    1. Brunner TB, Grabenbauer GG, Klein P, Baum U, Papadopoulos T, Bautz W, Hohenberger W, Sauer R. Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer(1) IntJRadiatOncolBiolPhys. 2003;55:144–153.
    1. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR AmJRoentgenol. 1997;168:1439–1443.
    1. Diehl SJ, Lehmann KJ, Sadick M, Lachmann R, Georgi M. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology. 1998;206:373–378.
    1. Valls C, Andia E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, Serrano T, Garcia-Borobia F, Jorba R. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol. 2002;178:821–826.
    1. Wutke R, Schmid A, Fellner F, Horbach T, Kastl S, Papadopoulos T, Hohenberger W, Bautz W. [CT-guided percutaneous core biopsy: Effective accuracy, diagnostic utility and effective costs] Rofo. 2001;173:1025–1033.
    1. Brunner TB, Merkel S, Grabenbauer GG, Meyer T, Baum U, Papadopoulos T, Sauer R, Hohenberger W. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based upon histopathologic analysis. IntJRadiatOncolBiolPhys. 2005;62:1021–1029.
    1. Hoffman JP, Pendurthi TK, Ross E, Yeung RS. Preoperative radiation therapy and chemotherapy for adenocarcinoma of the pancreas. Hepatogastroenterology. 1998;45:634–637.
    1. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB., III Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. JClinOncol. 1998;16:317–323.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj